Last reviewed · How we verify
Dulaglutide Pen
Dulaglutide Pen is a GLP-1 receptor agonist Small molecule drug developed by Eli Lilly and Company. It is currently FDA-approved for Type 2 diabetes mellitus, Cardiovascular risk reduction in patients with type 2 diabetes and established cardiovascular disease.
Dulaglutide activates GLP-1 receptors on pancreatic beta cells to increase insulin secretion and suppress glucagon in response to elevated blood glucose.
Dulaglutide activates GLP-1 receptors on pancreatic beta cells to increase insulin secretion and suppress glucagon in response to elevated blood glucose. Used for Type 2 diabetes mellitus, Cardiovascular risk reduction in patients with type 2 diabetes and established cardiovascular disease.
At a glance
| Generic name | Dulaglutide Pen |
|---|---|
| Sponsor | Eli Lilly and Company |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Dulaglutide is a long-acting GLP-1 receptor agonist that mimics glucagon-like peptide-1, a natural hormone that regulates blood sugar. By binding to GLP-1 receptors, it stimulates insulin release when glucose is high, inhibits glucagon secretion, and slows gastric emptying. This multi-mechanism approach reduces blood glucose levels in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
- Cardiovascular risk reduction in patients with type 2 diabetes and established cardiovascular disease
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Hypoglycemia
- Injection site reactions
Key clinical trials
- Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia (PHASE2)
- A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) (PHASE4)
- GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance (PHASE2)
- Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients (PHASE4)
- A Study of LY3437943 in Participants With Type 2 Diabetes (PHASE2)
- Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues (PHASE2)
- Effects of Glucagon-Like Peptide-1 Analogs on Sexuality (PHASE2)
- A Study Comparing the Dulaglutide Pen and the Semaglutide Pen (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dulaglutide Pen CI brief — competitive landscape report
- Dulaglutide Pen updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI
Frequently asked questions about Dulaglutide Pen
What is Dulaglutide Pen?
How does Dulaglutide Pen work?
What is Dulaglutide Pen used for?
Who makes Dulaglutide Pen?
What drug class is Dulaglutide Pen in?
What development phase is Dulaglutide Pen in?
What are the side effects of Dulaglutide Pen?
What does Dulaglutide Pen target?
Related
- Drug class: All GLP-1 receptor agonist drugs
- Target: All drugs targeting GLP-1R
- Manufacturer: Eli Lilly and Company — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
- Indication: Drugs for Cardiovascular risk reduction in patients with type 2 diabetes and established cardiovascular disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing